Filana Therapeutics, Inc. (FLNA) vs Metagenomi, Inc. Common Stock (MGX)

A side-by-side comparison of Filana Therapeutics, Inc. and Metagenomi, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Filana Therapeutics, Inc. logo
FLNA
Filana Therapeutics, Inc.
$42M
$0.86HealthcareDelayed quote: Oct 6, 2026, 11:04 AM EDT
Metagenomi, Inc. Common Stock logo
MGX
Metagenomi, Inc. Common Stock
$40M
$1.06HealthcareDelayed quote: Oct 6, 2026, 11:02 AM EDT

Total return — FLNA vs MGX

growth of $100 · dividends reinvested · last 1y
FLNA -57.6% (-57.6%/yr)MGX -28.3% (-28.3%/yr)MGX compounded faster over this window
406080100120Start $100$42$72
FLNA MGX

FLNA vs MGX: by the numbers

  • •FLNA is the larger company ($42M vs $40M market cap).
  • •Both run net losses; FLNA's is the smaller (0.00% vs -689.20% net margin).

Metrics side by side

Valuation

MetricFLNAMGX
P/S ratioN/A2.94
P/B ratio0.660.35

Profitability

MetricFLNAMGX
Gross margin0.00%74.29%
Operating margin0.00%-380.85%
Net margin0.00%-689.20%
ROE-66.47%-83.03%
ROIC-72.12%-66.03%

Go deeper

Full FLNA analysisFull MGX analysisInteractive comparison tool

Dig into the metrics

Filana Therapeutics ROEMetagenomi, Inc. Common Stock ROEFilana Therapeutics operating marginMetagenomi, Inc. Common Stock operating marginFilana Therapeutics revenue growthMetagenomi, Inc. Common Stock revenue growthFilana Therapeutics free cash flowMetagenomi, Inc. Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.